Jeff Boerneke

Jeff Boerneke’s practice includes representing investment banking firms, private equity firms, and companies in public and private debt and equity offerings, acquisition financing, mergers and acquisitions and corporate governance.

Boerneke’s experience includes the representation of:

·Cadence Pharmaceuticals in its sale to Mallinckrodt PLC for $1.4 billion

·Excel Trust in its $146 million follow-on and $250 million investment grade notes offerings

·Ignyta in its general corporate and securities matters and its $55 million public offering

·Zogenix in its sale of Sumavel DosePro to Endo Pharmaceuticals for $85 million and its acquisition of Brabant Pharma for $35 million in cash and stock, plus potential future milestone and royalty payments

·Goldman Sachs and Morgan Stanley in connection with a 1.5 billion euro initial public offering by Altice, a multinational cable and telecommunications company

·J.P. Morgan and Deutsche Bank in the offering by Unitymedia KabelBW of 1.5 billion euros (equivalent) in senior secured notes

·CVC Capital Partners in connection with the offering by Sunrise, a telecommunications operator in Switzerland, of approximately CHF 900 million in senior secured notes and approximately 500 million euros in PIK toggle notes

·Goldman Sachs in connection with an accelerated book-built offering (ABO) of a $1 billion package of shares in Seadrill, a leading offshore drilling company, which was named “Best Accelerated Deal” by EuroWeek in its EMEA Equity Capital Market Awards in 2011 and 2012, and in connection with an offering of $1 billion in senior notes by Seadrill.